<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107717</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20080456H</org_study_id>
    <nct_id>NCT01107717</nct_id>
  </id_info>
  <brief_title>Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM</brief_title>
  <official_title>Durability of Early Initial Combination Therapy With Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes is a systemic metabolic disease with significant morbidity and mortality due
      to damaging blood vessels. Increased blood sugar level is a hallmark of diabetes and is an
      contributes to the development of many of its complications. Multiple defects, e.g. impaired
      insulin secretion and impaired insulin action, contribute to the development of the disease.
      The aim of this study is to test the efficacy and durability of combination of drugs which
      correct the defects that lead to the development of diabetes on achieving adequate and
      durable control of blood sugar levels. Achieving adequate and durable control of blood sugar
      will prevent many of diabetes complications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in HbA1c level</measure>
    <time_frame>at the end of the dtudy (3 years)</time_frame>
    <description>subjects will be followed for 3 years and the difference in HbA1c between the two arms at 3 years is the primary outcome of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment failure</measure>
    <time_frame>at 6 months and 3 years</time_frame>
    <description>subjects with HbA1c &gt;6.5 at 6 months and 3 years are considered treatment failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypoglycemic events</measure>
    <time_frame>during the entire study (3 years)</time_frame>
    <description>asymptomatic hypoglycemic events with documented PGC &lt; 60 mg/dl and sympotomatic hypoglycemia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Triple Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>initiation a combination of metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) at the time diabetes is diagnosed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sequential addition of metformin, glyburide and basal insulin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin\pioglitazone\exenatide</intervention_name>
    <description>metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c &lt; 6.5%</description>
    <arm_group_label>Triple Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin, glyburide and glargine</intervention_name>
    <description>subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c &lt; 6.5%</description>
    <arm_group_label>conventional therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  subjects with type 2 diabetes diagnosed during the past 2 years,

          -  above 18 years of age,

          -  drug naive, or have been on metformin less than 3 months

        Exclusion Criteria:

          -  subjects with type 1 diabetes or GAD positive subjects or subjects with long standing
             diabetes (&gt;2 years) or subjects who are not drug naive or have been on metformin more
             than 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph DeFronzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Diabetes Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3900</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Abdul-Ghani, MD, PhD</last_name>
      <phone>210-567-2391</phone>
      <email>ABDULGHANI@UTHSCSA.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Curtiss Puckett, PA</last_name>
      <phone>(210) 358 7200</phone>
      <email>Curtiss.Puckett@uhs-sa.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ralph DeFronzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.diabetes.org/</url>
    <description>ADA Website</description>
  </link>
  <link>
    <url>http://uthscsa.edu</url>
    <description>university of texas web site</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2010</study_first_submitted>
  <study_first_submitted_qc>April 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2010</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Ralph DeFronzo</investigator_full_name>
    <investigator_title>Professor, Medicine -Diabetes</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>new onset</keyword>
  <keyword>combination therapy</keyword>
  <keyword>new onset type 2 diabetes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Glyburide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

